Metabolic syndrome and C-reactive protein in American adults: The impact of abdominal obesity

Metabolic Syndrome and Related Disorders

Volumn 6, Issue 4, 2008, Pages 289-297

  Okosun, Ike S ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

ABDOMINAL OBESITY; ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CIGARETTE SMOKING; CONTROLLED STUDY; DISEASE ASSOCIATION; ETHNICITY; FEMALE; HEALTH SURVEY; HUMAN; INFLAMMATORY DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SEX DIFFERENCE;

ADULT; BLOOD GLUCOSE; C-REACTIVE PROTEIN; FEMALE; HUMANS; INFLAMMATION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; REGRESSION ANALYSIS; RISK FACTORS; SMOKING; TRIGLYCERIDES; WEIGHT LOSS;

EID: 57449106361     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2008.0040     Document Type: Article

References (58)

1. Wannamethee SG. The metabolic syndrome and cardiovascular risk in the British Regional Heart Study. Int J Obes. 2008;32(suppl 2):S25-S29.
2. Eddy DM, Schlessinger L, Heikes K. The metabolic syndrome and cardiovascular risk: implications for clinical practice. Int J Obes 2008;32(suppl 2):S5-S10.
3. Ballantyne CM, Hoogeveen RC, McNeill AM, et al. Metabolic syndrome risk for cardiovascular disease and diabetes in the ARIC study. Int J Obes 2008;32(suppl 2):S21-S24.
4. Mozaffarian D, Kamineni A, Prineas RJ, et al. Metabolic syndrome and mortality in older adults: the Cardiovascular Health Study. Arch Intern Med 2008;168:969-978.
5. Wilson PW, Meigs JB. Cardiometabolic risk: a Framingham perspective. Int J Obes 2008;32(suppl 2):S17-S20.
6. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
7. Alberti K, Zimmet P, Shaw J. Metabolic syndrome - a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006;23:469-480.
8. Saad MF, Knowler WC, Pettitt DJ, et al. A two-step model for development of non-insulin-dependent diabetes. Am J Med. 1991;90:229-235
9. Kuller LH, Tracy RP, Shaten J, et al. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol 1996;144:537-547.
10. Katrinchak C, Fritz K. Clinical implications of C-reactive protein as a predictor of vascular risk. J Am Acad Nurse Pract 2007;19:335-340
11. Souza, JR, Oliveira RT, Blotta MH, Coelho OR. Serum levels of interleukin-6 (Il-6), interleukin-18 (Il-18) and C-reactive protein (CRP) in patients with type-2 diabetes and acute coronary syndrome without ST-segment elevation. Arq Bras Cardiol. 2008;90:86-90.
12. Sesso HD, Buring JE, Rifai N, et al. C-reactive protein and the risk of developing hypertension. JAMA 2003;290:2945-2951.
13. Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-242.
14. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-126.
15. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005;96:939-949.
16. Paffen E, DeMaat MP. C-reactive protein in atherosclerosis: A causal factor? Cardiovasc Res 2006;71:30-39.
17. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-454.
18. Uhlar CM., Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem1999;265:501-523
19. Mahadik SR, Deo SS, Mehtalia SD. Relation of C-reactive protein with the component of metabolic syndrome in Asian Indian subjects. Diabetes Met Syndrome: Clin Res Rev 2008;2:29-35.
20. Nakamura H, Ito H, Egami Y, et al. Waist circumference is the main determinant of elevated C-reactive protein in metabolic syndrome. Diabetes Res Clin Pract 2008;79:330-336.
21. Calabro P, Yeh ET. Intra-abdominal adiposity, inflammation, and cardiovascular risk: new insight into global cardiometabolic risk. Curr Hypertens Rep 2008;10:32-38.
22. Saltevo J, Vanhala M, Kautiainen H, et al. Gender differences in C-reactive protein, interleukin-1 receptor antagonist and diponectin levels in the metabolic syndrome: a population-based study. Diabet Med 2008;25:747-750.
23. Jenkins AJ, Rothen M, Klein RL, et al, DCCT/EDIC Research Group. Cross-sectional associations of C-reactive protein with vascular risk factors and vascular complications in the DCCT/EDIC cohort. J Diabetes Complications 2008;22:153-163.
24. Tonstad S, Sandvik E, Larsen PG, et al. Gender differences in the prevalence and determinants of the metabolic syndrome in screened subjects at risk for coronary heart disease. Metab Syndr Relat Disord 2007;5:174-182.
25. Erbel R, Möhlenkamp S, Lehmann N, et al. Sex related cardiovascular risk stratification based on quantification of atherosclerosis and inflammation. Atherosclerosis 2008;197:662-672.
26. Wee CC, Mukamal KJ, Huang A, et al. Obesity and C-reactive protein levels among white, black, and hispanic US adults. Obesity (Silver Spring). 2008;16:875-880.
27. Ramos RG, Olden K. The prevalence of metabolic syndrome among US women of childbearing age. Am J Public Health 2008;98:1122-1127.
28. Meng YX, Ford ES, Li C, Quarshie A, et al. Association of C-reactive protein with surrogate measures of insulin resistance among nondiabetic US from National Health and Nutrition Examination Survey 1999-2002. Clin Chem 2007;53:2152-2159.
29. Patel DA, Srinivasan SR, Xu JH, et al. Berenson GS. Distribution and metabolic syndrome correlates of plasma C-reactive protein in biracial (black-white) younger adults: the Bogalusa Heart Study. Metabolism 2006;55:699-705.
30. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359.
31. Center for Disease Control and Prevention: http://www.cdc.gov/nchs/about/ major/nhanes/nhanes2005-2006/nhanes05_06.htm/ (accessed May 29, 2008).
32. National Institute of Health/National Heart Lungs and Blood Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. The Evidence Report. Obesity Res 1998;6:51S-209S.
33. International Diabetes Federation, International Diabetes Federation Press Conference: The IDF consensus worldwide definition of the metabolic syndrome [article online], 2009. http://www.idf.org/home/index.cfm?node=1429/ (accessed May 29, 2009).
34. SAS Release 9.13. SAS Institute, Cary, NC.
35. Shah BV, Barnwell BG, Bieler GS. SUDAAN User's Manual. Research Triangle Institute, Research Triangle Park, NC.
36. Joy T, Lahiry P, Pollex RL, et al. Genetics of metabolic syndrome. Curr Diab Rep 2008;8:141-148.
37. Song SH, Hardisty CA. Diagnosing metabolic syndrome in type 2 diabetes: does it matter? QJM 2008;101:487-491.
38. Hoang KC, Ghandehari H, Lopez VA, et al. Global Coronary Heart Disease Risk Assessment of U.S. Persons With the Metabolic Syndrome. Diabetes Care 2008;31:1405-1414.
39. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004;110:1245-1250.
40. Martins D, Tareen N, Ogedegbe G, et al.. The relative risk of cardiovascular death among racial and ethnic minorities with metabolic syndrome: data from the NHANES-II mortality follow-up. J Natl Med Assoc 2008;100:565-571.
41. Pickup JC, Chusney GD, Thomas SM, et al. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci 2000:67:291-300.
42. Festa A, D'Agostino R Jr, Tracy RP, et al. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002:51:1131-1137.
43. You T, Yang R, Lyles MF, et al. Abdominal adipose tissue cytokine gene expression: relationship to obesity and metabolic risk factors. Am J Physiol Endocrinol Metab 2005;288:E741-E747.
44. Pitsavos C, Panagiotakos DB, Tzima N, et al. Diet, exercise, and C-reactive protein levels in people with abdominal obesity: the ATTICA epidemiological study. Angiology 2007;58:225-233
45. Santos AC, Lopes C, Guimarães JT, et al. Central obesity as a major determinant of increased high-sensitivity C-reactive protein in metabolic syndrome. Int J Obes 2005;29:1452-1456
46. Després JP. Cardiovascular disease under the influence of excess visceral fat. Crit Pathw Cardiol 2007;6:51-59
47. Theuma P, Fonseca VA. Inflammation, insulin resistance, and atherosclerosis. Metab Syndr Relat Disord 2004;2:105-113.
48. Kaaja RJ. Metabolic syndrome and the menopause. Menopause Int 2008;14:21-25.
49. Nakamura H, Ito H, Egami Y, et al. Waist circumference is the main determinant of elevated C-reactive protein in metabolic syndrome. Diabetes Res Clin Pract 2008;79:330-336.
50. Devaraj S, Swarbrick MM, Singh U, et al. CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers. Am J Clin Pathol. 2008;129:815-822
51. Kraja AT, Province MA, Arnett D, et al. Do inflammation and procoagulation biomarkers contribute to the metabolic syndrome cluster? Nutr Metab 2007:21;4:28.
52. Okamoto Y, Kihara S, Funahashi T, et al. Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci 2006;110:267-278.
53. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005;26:439-451.
54. Kahn SE, Zinman B, Haffner SM, et al. ADOPT Study Group. Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes. Diabetes 2006;55:2357-2364.
55. Onat A, Can G, Hergenç G. Serum C-reactive protein is an independent risk factor predicting cardiometabolic risk. Metabolism 2008;57:207-214.
56. Rutter MK, Meigs JB, Sullivan LM, et al. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004;110:380-385.
57. Laaksonen DE, Niskanen L, Nyyssonen K, et al., C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men, Diabetologia 2004:47:1403-1410.
58. Han TS, Sattar N, Williams K, et al. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study, Diabetes Care 2002;25:2016-2021.